ClinicalTrials.gg
RecruitingNCT06989892Updated May 25, 2025

Comparing Super High-flux and High-flux Dialyzer Performance Among Hemodialysis Patient With Sepsis : a Randomized Control Trial

An interventional study of Super High-flux dialyzer (Elisio 19HDx) and High-flux dialyzer (Elisio 19H) in The Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD, End Stage Kidney Disease (ESRD) and Sepsis, sponsored by Navamindradhiraj University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Navamindradhiraj University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Kidney Failure, Chronic with a site in Thailand — 4 open to participants now, 5 under way, 1 of them phase 3. Kidney Failure, Chronic · Thailand.

Planned enrollment
10th of 24
202 · median 130
Started
2024
with 2 others
No phase
12 of 29
3 open now
Registered
27th of 29
by date

Among the 29 studies in Kidney Failure, Chronic with a site in Thailand, this one is the 10th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, and was the 27th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

4 of the 29 studies in Kidney Failure, Chronic with a site in Thailand are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Kidney Failure, Chronic with a site in Thailand, or all of them as a file.
02

Study summary

Comparing the efficacy of superhigh-flux dialyzer with high-flux dialyzer in ESKD patient who have sepsis to improve mortality and sepsis outcome, an open label randomized control trial.

Read the detailed description

Sepsis in people who have ESKD is the risk of developing poor outcome. Cytokines play a role in the process of sepsis and cause the worsening clinical outcome despite definitive antibiotic treatment. Superhigh-flux dialyzer has a larger molecular weight cut off (MWCO) clearance, include cytokine, could contribute to improved sepsis management in individuals with ESKD. This study is conducted to prove the efficacy of super high-flux dialyzer comparing with high-flux dialyzer in case of mortality reduction for regular hemodialysis ESKD patients.

Method This study is an open label single center randomized control trial. We randomized ESKD patients who have sepsis condition with high interleukin-6 (IL-6 > 50 pg/ml).

The participants were allocated to super high-flux dialyzer group and high flux dialyzer group, stratified with diabetes, vascular access, and septic shock.

We excluded; patient who needed dialysis with continuous kidney replacement therapy, vulnerable patient, include pregnant woman, patient who closed and patient who expected to pass away within the 24 hours. We aim to enroll total 202 participants; divided equally in each arm. According to our protocol, non reused super high-flux dialyzer and high-flux dialyzer are used in the same assigned patient in first week without crossing over. The standard of care of sepsis and antibiotic are provided in both groups without intervening of researcher and our protocol. The primary endpoint is 28 days of mortality. The secondary outcome include cardiovascular death, rate reduction of IL-6 after dialysis, days of hospitalization, ventilator free days and complication of dialysis are also monitored.

03

Conditions studied

  • The Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD
  • End Stage Kidney Disease (ESRD)
  • Sepsis

Keywords

  • Superhighflux
  • hemodialysis
  • end stage kidney disease
  • sepsis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ESKD patients who have sepsis condition with high interleukin-6 (IL-6 > 50 pg/ml)

Exclusion criteria

Exclusion Criteria:

  • Patients who needed dialysis with continuous kidney replacement therapy, vulnerable patient, include pregnant woman, patient who expected to pass away within the 24 hours.
  • Patients who have the history of allergic dialyzer reaction to dialyzer which used in this trial.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
202 participants (estimated)

Study arms

  • Experimental
    ESKD patient with sepsis who dialyzed with super high flux

    Patients received dialysis with Superhigh-flux dialyzer

    Device: Super High-flux dialyzer (Elisio 19HDx)

  • Active comparator
    ESKD with sepsis who dialyzed with high flux dialyzer

    Patients received dialysis with High-flux dialyzer

    Device: High-flux dialyzer (Elisio 19H)

Interventions

  • DeviceSuper High-flux dialyzer (Elisio 19HDx)

    Dialysis with Super High-flux dialyzer for intervention group

  • DeviceHigh-flux dialyzer (Elisio 19H)

    Dialysis with High-flux dialyzer for control group

06

What researchers measure

Primary outcomes

  1. Comparing the reduction of all cause death at 28 days

    Comparing the efficacy to reduce all cause death at 28 days between Super High-flux dialyzer with High-flux dialyzer in ESKD with sepsis

    Time frame: 28 days

Secondary outcomes

  1. Comparing the difference of blood level of IL-6, ESR, CRP and albumin, before and after of the first dialysis session, in each group.

    Time frame: 7 days

  2. The duration of inotrope weaning

    Time frame: 14 days

  3. The duration of hospitalization

    Time frame: 28 days

  4. Ventilator free days

    Time frame: 28 days

  5. The incidence of intradialytic hypotension

    Time frame: 28 days

  6. The incidence rate of complication of dialyzer in each group

    The incidence rate of complication of dialyzer; allergic reaction, clotting of dialyzer etc.

    Time frame: 28 days

  7. The adequacy profile of dialysis in both groups

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • Navamindhradhiraj university
    Dusit, Bangkok 11130, Thailand
    Recruiting
    • Punnawit Laungchuaychok, MD · Contactpunnawit@nmu.ac.th · 022443000
    • Wanjak Pongsittisak, MD · Principal investigator
08

References and documents

Publications

  • Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013 Sep;41(9):2209-20. doi: 10.1097/CCM.0b013e31828cf412. PubMed 23860248 ↗
  • Gharamti AA, Samara O, Monzon A, Montalbano G, Scherger S, DeSanto K, Chastain DB, Sillau S, Montoya JG, Franco-Paredes C, Henao-Martinez AF, Shapiro L. Proinflammatory cytokines levels in sepsis and healthy volunteers, and tumor necrosis factor-alpha associated sepsis mortality: A systematic review and meta-analysis. Cytokine. 2022 Oct;158:156006. doi: 10.1016/j.cyto.2022.156006. Epub 2022 Aug 28. PubMed 36044827 ↗
  • Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000 Oct;58(4):1758-64. doi: 10.1111/j.1523-1755.2000.00337.x. PubMed 11012910 ↗
  • Song J, Park DW, Moon S, Cho HJ, Park JH, Seok H, Choi WS. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019 Nov 12;19(1):968. doi: 10.1186/s12879-019-4618-7. PubMed 31718563 ↗
  • Abe M, Masakane I, Wada A, Nakai S, Nitta K, Nakamoto H. Super high-flux membrane dialyzers improve mortality in patients on hemodialysis: a 3-year nationwide cohort study. Clin Kidney J. 2021 Sep 28;15(3):473-483. doi: 10.1093/ckj/sfab177. eCollection 2022 Mar. PubMed 35211304 ↗
  • Pongsittisak W, Satpanich P, Jaturapisanukul S, Keawvichit R, Prommool S, Trakranvanich T, Ngamvichukorn T, Kurathong S. Medium Cut-Off versus Low-Flux Dialyzers in Hemodialysis Patients with COVID-19: Clinical Outcomes and Reduction in Interleukin-6. Blood Purif. 2023;52(6):591-599. doi: 10.1159/000530162. Epub 2023 May 5. PubMed 37231799 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 23 months is close to that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
May 25, 2025
StartActual
Jul 25, 2024
Primary completionEst.
Jul 1, 2026
CompletionEst.
Oct 1, 2026
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06989892
Lead sponsor
Navamindradhiraj University
Responsible party
Punnawit Laungchuaychok (Dr., Navamindradhiraj University) — Principal investigator
First posted
May 25, 2025
Start date
Jul 25, 2024
Primary completion
Jul 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
May 25, 2025

Study contacts

Punnawit Laungchuaychok, MD
Contact
punnawit@nmu.ac.th
022443000
Wanjak Pongsittisak, MD
Contact
wanjak@nmu.ac.th
022443000
Punnawit Laungchuaychok, MD
principal investigator · Navamindradhiraj University
Wanjak Pongsittisak, MD
study chair · Navamindradhiraj University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion